| 000 | 01778 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518023814.0 | ||
| 264 | 0 | _c20200228 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a2164-554X | ||
| 024 | 7 |
_a10.1080/21645515.2019.1581541 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHu, Yuemei | |
| 245 | 0 | 0 |
_aImmunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study. _h[electronic resource] |
| 260 |
_bHuman vaccines & immunotherapeutics _c2019 |
||
| 300 |
_a1066-1069 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase IV; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAntibodies, Viral |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHemagglutination Inhibition Tests |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunogenicity, Vaccine |
| 650 | 0 | 4 |
_aInfluenza Vaccines _xadministration & dosage |
| 650 | 0 | 4 |
_aInfluenza, Human _xprevention & control |
| 650 | 0 | 4 | _aInjections, Intramuscular |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSeroconversion |
| 650 | 0 | 4 |
_aVaccines, Inactivated _ximmunology |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aChu, Kai | |
| 700 | 1 | _aLavis, Nathalie | |
| 700 | 1 | _aLi, Xiaoling | |
| 700 | 1 | _aLiang, Bill | |
| 700 | 1 | _aLiu, Shuzhen | |
| 700 | 1 | _aShao, Ming | |
| 700 | 1 | _aShu, Jean-Denis | |
| 700 | 1 | _aTabar, Cynthia | |
| 700 | 1 | _aSamson, Sandrine | |
| 773 | 0 |
_tHuman vaccines & immunotherapeutics _gvol. 15 _gno. 5 _gp. 1066-1069 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/21645515.2019.1581541 _zAvailable from publisher's website |
| 999 |
_c29387863 _d29387863 |
||